I am an independent investor, who enjoys following the stock market. I enjoy following. event-driven securities, corporate buyback plans, and equity with strong growth potential. I recently graduated Southern Methodist University in Dallas, TX. Follow me for stocks that interest me. Feel free to message me here.
I am a former sell-side analyst -- UBS 1996-2002, Needham 2002-2006 and ThinkEquity 2006-2008. These days I review automobiles and other technology products, as well as analyze the automotive and technology industries, and coming up with long/short ideas. I also continue to write (less frequently) on macroeconomics and politics.
As Managing Editor - Opinion and Analysis, I lead the Seeking Alpha team dedicated to curation of crowdsourced investment research and commentary. My responsibilities are to grow the site's audience, deepen user engagement, and improve editorial processes. I am a CFA charterholder and member of the CFA Society Washington, DC.
To follow me click the "Follow" button! (Easy right?)
Kumquat Research is a college student and fund manager who has been investing for 5 years. He writes mostly about the technology sector and about event-driven and momentum opportunities across various industries and sectors. He is currently studying for degrees in both finance and computer science at the University of Maryland. Some of his interests include technology, programming, drumming, video games (developing and playing) and astronomy. Articles written and comments posted by Kumquat Research are NOT financial or investment advice, and only express his opinion. Do your own due diligence!
I'm retired from a near 40 year career in the publishing industry working with an international publishing company. My investing experience is over a span of 40 years. Luckily with more winners than losers! My hobbies are world travel, reading good books(non-fiction)--and researching stocks that I have an interest. In my retirement, I volunteer my time working in assisting several lawyers with their Child Protective Service cases.(Drugs are destroying our Society and family structure) I also serve as a reviewer for a national literary prize given each year.
Professionally, I have done a bit of everything in my long life, from playing rock and roll, to developing software, and running a successful entrepreneurial business. But I am best known as a writer of bestselling books about business and health. I write under a pseudonym here on Seeking Alpha because that way I know readers will evaluate my work strictly on the basis of what I actually said rather than who I am.
I write on a lot of different investing topics, so if you decide to follow me, drop me a line to let me know what topics you'd like me to write about more.
Bishop Research & Analytics delivers comprehensive investment analysis on small and mid-cap companies, equity research, market trends, and valuation models. Our professional research provides investment managers with in-depth insights, detailed research, and timely market intelligence to outperform the benchmark indices and gain the advantage of leading the markets.
10 years of buy-side investment experience.
Disclaimer: Any content on this site is NOT investment, trading, legal, or tax advice, and none of the information available through this website is intended to provide tax, legal, investment or trading advice. Nothing provided through this content whether by the owner or posted by other writers constitutes a solicitation of the purchase or sale of securities/futures. The content on this site is intended for informational purposes only, and should never be used as investment advice. Please do your own research before making any investment decisions.
Independent writer/trader/investor that tends to write more for informational purposes than to advance a particular trading position. My positions can change dramatically as new information comes to my attention. All stocks are risky. Please, don't follow me into a penny stock without realizing they are HIGHLY risky and you can lose ALL of your investment. No payment in any form is accepted for my writing by any company or other party. I only receive that which comes from writing on Seeking Alpha.
I’M NOT A FINANCIAL ADVISOR OR SCIENTIST & ONLY GIVE MY OPINIONS. SEEK EXPERT ADVICE ELSEWHERE. ;)
Investment Philosophy: Understand why you are getting in.
Please click to follow me if you like my work. There’s an option to do so at the top of my articles. Best functionality of site is on desktop.
Education is an undergraduate degree in Business Administration and Management. Masters' in Organizational Management.
Be kinder than necessary, for everyone you meet is fighting some kind of battle. ;)
I am an investor who has a passion for discovering and investing in the compelling and breakthrough companies of our time. I share my humble (and often times not so humble) opinions to help others to ask their own questions as they conduct their own due diligence.
Disclaimer: Articles provide opinions and information, but do not contain recommendations or personal investment advice to any specific person for any particular purpose. Do your own research and/or obtain suitable personal advice from an investment professional.
James Altucher was the managing director of Formula Capital, an asset management firm and fund of hedge funds. He's written five books on investing: Trade Like a Hedge Fund, Trade Like Warren Buffett, SuperCash, The Forever Portfolio, and his latest book, The Choose Yourself Guide To Wealth. He currently writes at Jamesaltucher.com and has released a newsletter, The Altucher Report.
Mr. Altucher is the founder of Stockpickr.com, a social network for finance that had millions of unique visitors per month when it was sold to TheStreet.com in 2007. He has written over 200 columns for The Financial Times and has written for TheStreet.com, Forbes, Yahoo Finance, Fidelity.com, and other publications. He was also the founder of a web services firm, Reset Inc, which he sold in 1998, at which time he became a partner at VC firm, 212 Ventures/Investcorp. Mr. Altucher regularly appears on CNBC, Fox News, Fox Business, and CNN Radio, and is also in his spare time a nationally ranked chess master. Mr. Altucher received his BA at Cornell University and attended graduate school for computer science at Carnegie Mellon University.
You can follow him on twitter @jaltucher.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
I am currently a Junior at the George Washington University and have been investing since the sixth grade with my own money. I am very interested in the pharmaceutical sectors, but will buy just about any stock if I feel that the company is undervalued. I hope to provide some helpful insight, and to in turn learn a lot from the rest of the investment community.
Richard Zeits is an Oil & Gas industry analyst and consultant. His background includes fourteen years as Energy industry-focused investment banker, portfolio manager and senior investment analyst with bulge bracket firms in New York. Zeits Energy Analytics use elaborate proprietary analytics and data bases to provide in-depth industry research, market intelligence, and forecasting.
It is very hard or impossible to time the broad market consistently — there are no famous investors that got rich by consistently knowing what the broad market would do next. This only makes sense, as there are just too many variables in the broad market. But there are many famous investors who got rich analyzing individual securities, and this is where you should put your focus. You can get an edge in individual securities. Joe Springer was the number 1 ranked stock analyst in the world by tipranks.com. Joe is a Certified Technical Trainer, and enjoys teaching about the stock market as well as managing portfolios. If you would like to follow Joe on Twitter, his handle is @JoeSpringer.
Over 15 years as an IT Consultant for a wide range of clients including Dell, Ingram Micro, BankAm South and FedEx Data Center. Specializes in technology, contrarian plays and global macro. My articles have appeared on Morningstar.com, IHIQS, Seeking Alpha, Yahoo! Finance, MarketWatch, EIN Newsdesk, Google Finance, Motley Fool, MSN Money, and AOL Daily Finance.
I began my professional career as a capital markets lawyer at the New York firm Cadwalader, Wickersham & Taft. In 2010, I returned to Notre Dame (’05 undergrad) for my MBA and graduated ('12) with an Investments concentration. I currently work as an equity analyst for an asset manager.
Please feel free to connect with me here or elsewhere--my linkedin profile is below:
Helping conceive disruptive innovations, establishing product strategy, setting go-to-market goals with sales, and maximizing revenue contribution of financial services related product lines of the company. Currently based out of Iowa.
Passionate about the stock market and business trends, writes for SeekingAlpha and MotleyFool. MBA from University of Florida, Warrington School of Business.
Twitter updates: @hitjo
Jeff is the President of NewArc Investments Inc., manager of both individual and institutional investments. Jeff is a registered investment advisor, and portfolio manager for NewArc's investment programs. Jeff is a former college professor with a hands-on, real world attitude. His quantitative modeling helped inform state and local officials in Wisconsin for more than a decade. A Public Policy analyst, he taught advanced research methods at the University of Wisconsin, and analyzed many issues related to state tax policy. Jeff began in the financial business as Research Director for trading firm at the Chicago Board Options Exchange. He investigated anomalies in the standard option pricing models, taught classes for beginning options traders, and developed new forecasting techniques. In 1991 he established a general research consultancy, working with professional traders at all of the Chicago financial exchanges. In 1998 he started NewArc Investments, Inc. Jeff has a commitment to the specific needs of individual investors. It is not a one-size-fits all approach, but one that emphasizes the unique circumstances of each client. Jeff also serves on the board of two small technology companies (currently Chairman at one). He is occasionally as an expert witness in legal cases involving financial markets and hedging.
Any article created here is for informational and educational purposes only and shall not be construed to constitute investment advice. Nothing contained within an article, comment, or posting shall constitute a solicitation, recommendation or endorsement to buy or sell any security.
Stephen Simpson, CFA, is a freelance financial writer and investor.
I have worked for both sell-side and buy-side firms (equities and fixed income), with the largest percentage of my working time spent in med-tech. At this point I am now effectively in a "working retirement".
I write because I find that the process helps me take better notes, be more disciplined about modeling, and come up with a more coherent investment view for my portfolio management needs. If I'm writing about a stock, it's generally because I'm interested in it as an investment prospect or I think there's an interesting story to tell.
I don't share my models, so please don't ask.
More of my writings can be found at my blog Kratisto Investing (kratistoinvesting.blogspot.com), or Twitter (@Kratisto_Invest).
Edward Harrison is the founder of the blog Credit Writedowns (www.creditwritedowns.com) and is a finance specialist at Global Macro Advisors. Previously, Edward was a strategy and finance executive at Deutsche Bank, Bain, and Yahoo. He started his career as a diplomat and speaks German, Dutch, Swedish, Spanish and French. Edward holds an MBA from Columbia University and a BA in Economics from Dartmouth College. Follow him on Twitter at twitter.com/edwardnh. Contact him at edh at creditwritedowns dot com as that's the only mailbox he reads regularly.
Marc Chandler has been covering the global capital markets in one fashion or another for 25 years, working at economic consulting firms and global investment banks. A prolific writer and speaker he appears regularly on CNBC and has spoken for the Foreign Policy Association. In addition to being quoted in the financial press daily, Chandler has been published in the Financial Times, Foreign Affairs, and the Washington Post. In 2009 Chandler was named a Business Visionary by Forbes.
Marc's commentary can be found at his blog (www.marctomarket.com) and twitter www.twitter.com/marcmakingsense
Jaime Macrae is an Account Executive at Friedberg Mercantile Group. He has been actively involved in trading currency and commodity futures for several years, and has spent most of his career working for one of Canada's largest investment banks. He is also an active blogger, writing daily about commodity and currency markets.
Alan Brochstein, CFA, was the first investment professional to devote himself to sharing his observations about the cannabis industry from an investor's perspective publicly. He runs 420 Investor, a subscription-based due diligence platform for investors interested in the publicly-traded cannabis stocks and is also the founder of New Cannabis Ventures, a content aggregation site focused on investors and entrepreneurs in the cannabis industry.
Alan has worked in the securities industry since 1986, primarily with the responsibility for managing investments in institutional environments until he founded AB Analytical Services in 2007 in order to provide independent research and consulting to registered investment advisors. In addition to advising several different hedge funds and investment managers, including Friedberg Investment Management, where he participated as a member of its investment management committee, Alan was also a senior analyst for the independent research firm Management CV. In 2008, he began providing a first-of-its-kind subscription-based service for individual investors, Invest By Model, which offered two different portfolios that investors could replicate in their own accounts for $20 per month. Alan also offered The Analytical Trader at Marketfy, where he used fundamental and technical analysis in a disciplined process to offer specific trade ideas geared towards swing traders.
Alan launched www.420Investor.com in late 2013 as the premier source of information for "Green Rush" investors seeking to capitalize on the proliferation of legalized medical and recreational cannabis. In March 2014, Alan, who is a member of the National Cannabis Industry Association, began to focus solely on the cannabis sector. He launched www.NewCannabisVentures.com in late 2015.
You can follow Alan on Facebook (www.facebook.com/420investor) or on Twitter (https://twitter.com/Invest420). Alan also moderates a large LinkedIn group focused on the cannabis industry, Cannabis Investors & Entrepreneurs (https://www.linkedin.com/groups/6523904)
I am the founder and editor of Investment Directions. My career has been managing and consulting to multi-billion dollar funds. Using the widely accepted “multi-manager” approach, I have worked with top investment managers throughout the country, gaining a high level of expertise.
My career has spanned many market environments, and I have hands-on experience searching out opportunities and avoiding risks in all of them. I now devote my time to Investment Directions, with the goal of helping investors further their understanding and improve their investing skills.
I am currently serving on: The AAUW Investment Advisers Committee and The City of Vista Investment Advisory Committee.
The Burrill Report is written for everyone who wants to understand how biotechnology operates as a business. Each month the publication focuses on the health of the industry and the strategies that will be needed to be successful. It provides actionable market intelligence on the latest global developments and trends in the life sciences industry. Available monthly, subscribers also benefit from monthly and quarterly market financial and business statistics on:
- Public companies
- venture financings
- Project Runway – Follow the global life sciences companies filing for and completing their IPOs – and their post market performances
- Clinical Trials successes and failures
- M&A and Partnering deals
- Periodic country features on Canada, Europe and emerging countries such as China & India.
In addition, BR provides in-depth coverage on specific sectors of life sciences including: Personalized Medicine; Diagnostics, Medical Devices and Biogreentech (Ag-Bio and Biofuels/Bioenergy). Through weekly Burrill Indices, the progress and prospects of biotech companies by size, from small through to blue-chip are also tracked.
Visit: The Burrill Report to obtain your sample issue (http://www.burrillreport.com/)
Steven currently focuses his analyses primarily on the valuation of smaller biotechs (100MM to 1 BB market cap) and utilizes all sources of information, including conversations with management, peer-reviewed publications, SEC filings, and all available primary and secondary research.
Steven is currently a consultant for a New York based life science focused consultancy, and brings a strong scientific and financial background to his current position.
Previously, Steven earned a Ph.D. from the Scripps Research Institute and an M.A. from Columbia University, with extensive work in the field of synthetic and medicinal chemistry, publishing several papers in prestigious peer-reviewed journals. He is also pursuing the CFA designation, and has completed exam level 2.
Please email me with any questions, comments, and investment ideas. (stevenb29 at gmail.com)